Krystal Biotech (KRYS) Free Cash Flow (2016 - 2026)

Krystal Biotech has reported Free Cash Flow for 11 years, with the latest figure at $71.2 million in Q2 2026.

• Free Cash Flow for Q2 2026 came in at $71.2 million, up 40.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $257.8 million (up 37.59% YoY), and the FY2025 annual result was $188.9 million, up 64.38% from the prior year.
• Free Cash Flow slipped to $71.2 million in Q2 2026, from $73.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $75.4 million in Q4 2025 and troughed at -$59.6 million in Q2 2022.
• A 5-year average of $10.8 million and a median of $1.6 million in 2024 frame the typical range for Free Cash Flow.
• The widest annual swing landed in 2022, when Free Cash Flow tumbled 237.4%; it then jumped 1287.5% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$27.5 million in 2022, then surged by 71.22% to -$7.9 million in 2023, then jumped by 763.95% to $52.6 million in 2024, then soared by 43.18% to $75.4 million in 2025, then decreased by 5.5% to $71.2 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $71.2 million in Q2 2026, $73.2 million in Q1 2026, and $75.4 million in Q4 2025.